Head to Head Analysis: Oruka Therapeutics (NASDAQ:ORKA) and Cardio Diagnostics (NASDAQ:CDIO)

Oruka Therapeutics (NASDAQ:ORKA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Valuation and Earnings

This table compares Oruka Therapeutics and Cardio Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	N/A	N/A
Cardio Diagnostics	$39,138.00	152.62	-$8.38 million	N/A	N/A

Oruka Therapeutics has higher earnings, but lower revenue than Cardio Diagnostics.

Insider & Institutional Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Oruka Therapeutics and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Cardio Diagnostics	-22,358.43%	-312.97%	-189.57%

Analyst Ratings

This is a breakdown of recent recommendations for Oruka Therapeutics and Cardio Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	4	2	3.33
Cardio Diagnostics	0	0	1	0	3.00

Oruka Therapeutics presently has a consensus price target of $41.25, suggesting a potential upside of 73.03%. Cardio Diagnostics has a consensus price target of $2.00, suggesting a potential upside of 659.59%. Given Cardio Diagnostics’ higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Oruka Therapeutics.

Risk and Volatility

Oruka Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 4.87, indicating that its stock price is 387% more volatile than the S&P 500.

Summary

Oruka Therapeutics beats Cardio Diagnostics on 7 of the 12 factors compared between the two stocks.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.